Company also announces appointment of Dr.
John Mull as Chair of the Board of
Directors
MISSISSAUGA, ON, Sept. 1, 2016 /PRNewswire/ - Cipher
Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the
Company") today announced that Stephen L.
Lemieux, BA, MMPA, CPA, has been appointed Chief Financial
Officer and Secretary of the Company, effective September 12, 2016. Mr. Lemieux replaces
Norman Evans, who, as previously
announced, is retiring after almost 10 years as the Chief Financial
Officer of Cipher. Mr. Evans will continue with Cipher in a
consulting capacity to ensure a smooth transition of
responsibilities.
Mr. Lemieux, who has more than 13 years of public company
experience, most recently served as Vice President and Chief
Financial Officer of Nuvo Pharmaceuticals (TSX:NRI) ("Nuvo"), a
commercial healthcare company with a portfolio of commercial
products and pharmaceutical manufacturing capabilities. He was
appointed Chief Financial Officer of Nuvo in January 2012. In his role, Mr. Lemieux was
responsible for all of Nuvo's financial operations as well as
information technology, manufacturing, human resources and
planning. Mr. Lemieux's transactional experience includes licensing
and asset sales, debt and equity financing, acquisitions, corporate
reorganizations and plans of arrangement.
"We are very pleased to add Stephen to the Cipher team," said
Shawn Patrick O'Brien, President and
CEO of Cipher. "His extensive public company experience,
pharmaceutical industry knowledge and strong transaction background
make him an excellent fit, and we look forward to his contributions
as we grow the business."
"It's an exciting time to join Cipher and I look forward to
working with Shawn and the team to execute the growth strategy,"
said Mr. Lemieux.
Prior to joining Nuvo in 2007, Mr. Lemieux was the Corporate
Controller at Martinrea International Inc., a Tier One automotive
supplier. Prior to joining Martinrea, Mr. Lemieux was the Assistant
Controller at Magna Powertrain (formerly Tesma International Inc.)
and had previously held the position of Manager, Global Financial
Reporting. Tesma was a Tier One automotive supplier and a public
company listed on the TSX and NASDAQ. Prior to joining Tesma, Mr.
Lemieux worked for Ernst & Young performing audit,
restructuring and accounting work for its clients. Mr. Lemieux is a
Chartered Professional Accountant and holds a Master of Management
& Professional Accounting from the University of Toronto.
Further to the August 9, 2016
press release on changes to Cipher's board of directors, the
Company also announced that Dr. John
Mull has been appointed Chair of the board.
"I look forward to working with my fellow directors and Cipher's
senior management team to enhance value for all our shareholders,"
said Dr. Mull.
About Cipher Pharmaceuticals Inc.
Cipher
Pharmaceuticals (NASDAQ:CPHR;TSX:CPH) is a rapidly growing
specialty pharmaceutical dermatology company with a diversified
portfolio of commercial-stage products with the goal of becoming
the most customer-centric dermatology company in North
America.
Through multiple transactions, including the acquisition of
Innocutis and its nine branded dermatology products, Cipher has
built its U.S. commercial presence, expanded its Canadian
dermatology franchise and broadened its pipeline. Cipher is
well-capitalized to drive long-term, sustained earnings growth by
leveraging its proven clinical development capabilities and
efficient commercial execution. For more information,
visit www.cipherpharma.com.
SOURCE Cipher Pharmaceuticals Inc.